相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines
Hua Cheng et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma
Sung-Jin Park et al.
CANCER LETTERS (2010)
Genistein and β-carotene enhance the growth-inhibitory effect of trichostatin A in A549 cells
Rong-Jen Shiau et al.
EUROPEAN JOURNAL OF NUTRITION (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage
Cheng-Yun Jin et al.
ANTI-CANCER DRUGS (2009)
被撤回的出版物: Genistein Enhances the Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Inhibits Nuclear Factor Kappa B in Nonsmall Cell Lung Cancer Cell Lines (Retracted article. See vol. 122, pg. 3248, 2016)
Shirish M. Gadgeel et al.
CANCER (2009)
被撤回的出版物: Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents (Retracted article. See vol. 423, pg. 154, 2018)
Shadan Ali et al.
CANCER LETTERS (2009)
Evidence that low-dose, long-term genistein treatment inhibits oestradiol-stimulated growth in MCF-7 cells by down-regulation of the PI3-kinase/Akt signalling pathway
Nitharnie Anastasius et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2009)
Kaempferol Induces Cell Death Through ERK and Akt-Dependent Down-Regulation of XIAP and Survivin in Human Glioma Cells
Ji Cheon Jeong et al.
NEUROCHEMICAL RESEARCH (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals
Jian-Quan Zhu et al.
CANCER LETTERS (2008)
Multi-targeted therapy of cancer by genistein
Sanjeev Banerjee et al.
CANCER LETTERS (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D. Li et al.
ONCOGENE (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
Jeffrey A. Engelman et al.
CANCER RESEARCH (2007)
Epidermal growth factor receptor double activating mutations involving both Exons 19 and 21 exist in chinese non-small cell lung cancer patients
G-C. Zhang et al.
CLINICAL ONCOLOGY (2007)
Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells
Tianhong Li et al.
CLINICAL CANCER RESEARCH (2007)
Lung cancer in the elderly
Cesare Gridelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
Ulrich Gatzemeier et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
被撤回的出版物: Potentiation of the effect of erlotinib by genistein in pancreatic cancer:: The role of Akt and nuclear factor-κB (Retracted article. See vol. 78, pg. 5472, 2018)
Basil F. El-Rayes et al.
CANCER RESEARCH (2006)
Using chemopreventive agents to enhance the efficacy of cancer therapy
FH Sarkar et al.
CANCER RESEARCH (2006)
Neonatal estrogenic exposure suppresses PTEN-related endometrial carcinogenesis in recombinant mice
M Begum et al.
LABORATORY INVESTIGATION (2006)
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein (TM)) in healthy volunteers
U Ullmann et al.
ADVANCES IN THERAPY (2005)
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1
G Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
PI3K/Akt and apoptosis: size matters
TF Franke et al.
ONCOGENE (2003)
Mechanisms of cancer chemoprevention by soy isoflavone genistein
FH Sarkar et al.
CANCER AND METASTASIS REVIEWS (2002)
New treatment approaches for lung cancer and impact on survival
H Cortés-Funes
SEMINARS IN ONCOLOGY (2002)
Current standards of care in small-cell and non-small-cell lung cancer
JH Schiller
ONCOLOGY (2001)
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
FV Fossella et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
